Because multiple cancer gene panel testing is rapidly replacing sequential single-gene testing, we need to know how to improve in the way we interpret the findings from panel testing patients in cancer kindreds who have been previously tested for the BRCA1/2, PTEN, TP53 and MMR genes without detection of pathogenic variants. This evidence concerns the gene TP53 and cancer.